Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas

BMC Cancer

Volumn 9, Issue , 2009, Pages 368-

  Österberg, Lovisa ^a   Levan, Kristina ^a   Partheen, Karolina ^a   Delle, Ulla ^a   Olsson, Björn ^b   Sundfeldt, Karin ^a   Horvath, György ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF SKÖVDE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROTEIN SH3; PROTEIN SH3GL2; PROTEIN SH3KBP1; TRANSCRIPTION FACTOR GLI2; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CHROMOSOME 3Q; CHROMOSOME 6Q; CHROMOSOME 9P; CHROMOSOME ADDITION; CHROMOSOME LOSS; CHROMOSOME XP; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; MULTIDRUG RESISTANCE; OVARY CANCER; OVARY CARCINOMA; PREDICTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

EID: 70450257689     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-368     Document Type: Article

References (51)

1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 1996, 23(5 Suppl 12):40-47.
2. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000, 92(9):699-708. 10.1093/jnci/92.9.699, 10793106.
3. Heintz APM, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngain HYS, Pecorelli S, Beller U. Carcinoma of the ovary. Int J Gynaecol Obstet 2006, 95 Suppl 1:S161-S192. 10.1016/S0020-7292(06)60033-7, 17161157.
4. Nogales E, Wolf SG, Downing KH. Structure of the alpha beta tubulin dimer by electron crystallography. Nature 1998, 391(6663):199-203. 10.1038/34465, 9428769.
5. Galletti E, Magnani M, Renzulli ML, Botta M. Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem 2007, 2(7):920-942. 10.1002/cmdc.200600308, 17530726.
6. Luqmani YA. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 2005, 14(Suppl 1):35-48. 10.1159/000086183, 16103712.
7. Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990, 40(10):2353-2362. 10.1016/0006-2952(90)90733-2, 2244936.
8. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol 2000, 60(9):1305-1313. 10.1016/S0006-2952(00)00441-X, 11008124.
9. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996, 56(3):556-562.
10. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1992, 89(7):3070-3074. 10.1073/pnas.89.7.3070, 48805, 1348364.
11. Katano K, Safaei R, Samimi G, Holzer A, Rochdi M, Howell SB. The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol Pharmacol 2003, 64(2):466-473. 10.1124/mol.64.2.466, 12869652.
12. Bernardini M, Lee CH, Beheshti B, Prasad M, Albert M, Marrano P, Begley H, Shaw P, Covens A, Murphy J. High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia 2005, 7(6):603-613. 10.1593/neo.04760, 1501280, 16036111.
13. Kim SW, Kim JW, Kim YT, Kim JH, Kim S, Yoon BS, Nam EJ, Kim HY. Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease. Genes Chromosomes Cancer 2007, 46(1):1-9. 10.1002/gcc.20384, 17044060.
14. Prasad M, Bernardini M, Tsalenko A, Marrano P, Paderova J, Lee CH, Ben-Dor A, Barrett MT, Squire JA. High definition cytogenetics and oligonucleotide aCGH analyses of cisplatin-resistant ovarian cancer cells. Genes Chromosomes Cancer 2008, 47(5):427-436. 10.1002/gcc.20547, 18273836.
15. Osterberg L, Levan K, Partheen K, Staaf J, Sundfeldt K, Horvath G. High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma. Cytogenet Genome Res 2009, 125(1):8-18. 10.1159/000218744, 19617691.
16. Kudoh K, Takano M, Koshikawa T, Hirai M, Yoshida S, Mano Y, Yamamoto K, Ishii K, Kita T, Kikuchi Y. Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients. Clin Cancer Res 1999, 5(9):2526-2531.
17. Wasenius VM, Jekunen A, Monni O, Joensuu H, Aebi S, Howell SB, Knuutila S. Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells. Genes Chromosomes Cancer 1997, 18(4):286-291. 10.1002/(SICI)1098-2264(199704)18:4<286::AID-GCC6>3.0.CO;2-X, 9087568.
18. Takano M, Kudo K, Goto T, Yamamoto K, Kita T, Kikuchi Y. Analyses by comparative genomic hybridization of genes relating with cisplatin-resistance in ovarian cancer. Hum Cell 2001, 14(4):267-271.
19. Osterberg L, Levan K, Partheen K, Helou K, Horvath G. Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma. Cancer Genet Cytogenet 2005, 163(2):144-150. 10.1016/j.cancergencyto.2005.06.023, 16337857.
20. Jonsson G, Staaf J, Olsson E, Heidenblad M, Vallon-Christersson J, Osoegawa K, de Jong P, Oredsson S, Ringner M, Hoglund M. High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer 2007, 46(6):543-558. 10.1002/gcc.20438, 17334996.
21. Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A, Peterson C. BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biology 2002, 3(8). 10.1186/gb-2002-3-8-software0003, 139402, 12186655.
22. Staaf J, Jonsson G, Ringner M, Vallon-Christersson J. Normalization of array-CGH data: influence of copy number imbalances. BMC Genomics 2007, 8:382. 10.1186/1471-2164-8-382, 2190775, 17953745.
23. Autio R, Hautaniemi S, Kauraniemi P, Yli-Harja O, Astola J, Wolf M, Kallioniemi A. CGH-Plotter: MATLAB toolbox for CGH-data analysis. Bioinformatics 2003, 19(13):1714-1715. 10.1093/bioinformatics/btg230, 15593402.
24. Gunnarsson R, Staaf J, Jansson M, Ottesen AM, Goransson H, Liljedahl U, Ralfkiaer U, Mansouri M, Buhl AM, Smedby KE. Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia--a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer 2008, 47(8):697-711. 10.1002/gcc.20575, 18484635.
25. Willenbrock H, Fridlyand J. A comparison study: applying segmentation to array CGH data for downstream analyses. Bioinformatics 2005, 21(22):4084-4091. 10.1093/bioinformatics/bti677, 16159913.
26. Frank E, Hall M, Trigg L, Holmes G, Witten IH. Data mining in bioinformatics using Weka. Bioinformatics 2004, 20(15):2479-2481. 10.1093/bioinformatics/bth261, 15073010.
27. Partheen K, Levan K, Osterberg L, Helou K, Horvath G. Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage. Genes Chromosomes Cancer 2004, 40(4):342-348. 10.1002/gcc.20053, 15188458.
28. Gehan EA. A Generalized Wilcoxon Test for Comparing Arbitrarily Singly-Censored Samples. Biometrika 1965, 52:203-223.
29. Partheen K, Levan K, Osterberg L, Horvath G. Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. Eur J Cancer 2006, 42(16):2846-2854. 10.1016/j.ejca.2006.06.026, 16996261.
30. Nanjundan M, Nakayama Y, Cheng KW, Lahad J, Liu J, Lu K, Kuo WL, Smith-McCune K, Fishman D, Gray JW. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res 2007, 67(7):3074-3084. 10.1158/0008-5472.CAN-06-2366, 17409414.
31. Sunde JS, Donninger H, Wu K, Johnson ME, Pestell RG, Rose GS, Mok SC, Brady J, Bonome T, Birrer MJ. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res 2006, 66(17):8404-8412. 10.1158/0008-5472.CAN-06-0683, 16951150.
32. Brooks DJ, Woodward S, Thompson FH, Dos Santos B, Russell M, Yang JM, Guan XY, Trent J, Alberts DS, Taetle R. Expression of the zinc finger gene EVI-1 in ovarian and other cancers. Br J Cancer 1996, 74(10):1518-1525. 2074868, 8932329.
33. Liu Y, Chen L, Ko TC, Fields AP, Thompson EA. Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT. Oncogene 2006, 25(25):3565-3575. 10.1038/sj.onc.1209403, 16462766.
34. Soubeyran P, Kowanetz K, Szymkiewicz I, Langdon WY, Dikic I. Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature 2002, 416(6877):183-187. 10.1038/416183a, 11894095.
35. Cao C, Lu S, Sowa A, Kivlin R, Amaral A, Chu W, Yang H, Di W, Wan Y. Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs. Cancer Lett 2008, 266(2):249-262. 10.1016/j.canlet.2008.02.062, 2519958, 18400375.
36. Chan JK, Pham H, You XJ, Cloven NG, Burger RA, Rose GS, Van Nostrand K, Korc M, Disaia PJ, Fan H. Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model. Cancer Res 2005, 65(8):3243-3248.
37. Huang KC, Rao PH, Lau CC, Heard E, Ng SK, Brown C, Mok SC, Berkowitz RS, Ng SW. Relationship of XIST expression and responses of ovarian cancer to chemotherapy. Mol Cancer Ther 2002, 1(10):769-776.
38. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 2005, 11(6):2149-2155. 10.1158/1078-0432.CCR-04-1673, 15788660.
39. Tetu B, Popa I, Bairati I, L'Esperance S, Bachvarova M, Plante M, Harel F, Bachvarov D. Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas. Mod Pathol 2008, 21(8):1002-1010. 10.1038/modpathol.2008.80, 18500265.
40. Yang YL, Chu JY, Luo ML, Wu YP, Zhang Y, Feng YB, Shi ZZ, Xu X, Han YL, Cai Y. Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma. Genes Chromosomes Cancer 2008, 47(2):127-136. 10.1002/gcc.20514, 17990328.
41. Gray JW, Suzuki S, Kuo WL, Polikoff D, Deavers M, Smith-McCune K, Berchuck A, Pinkel D, Albertson D, Mills GB. Specific keynote: genome copy number abnormalities in ovarian cancer. Gynecol Oncol 2003, 88(1 Pt 2):s16-21. discussion S22-14., 10.1006/gyno.2002.6677, 12586079.
42. Larramendy ML, Lushnikova T, Bjorkqvist AM, Wistuba II, Virmani AK, Shivapurkar N, Gazdar AF, Knuutila S. Comparative genomic hybridization reveals complex genetic changes in primary breast cancer tumors and their cell lines. Cancer Genet Cytogenet 2000, 119(2):132-138. 10.1016/S0165-4608(99)00226-5, 10867149.
43. Nucifora G, Laricchia-Robbio L, Senyuk V. EVI1 and hematopoietic disorders: history and perspectives. Gene 2006, 368:1-11. 10.1016/j.gene.2005.09.020, 16314052.
44. Yokoi S, Yasui K, Iizasa T, Imoto I, Fujisawa T, Inazawa J. TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers. Clin Cancer Res 2003, 9(13):4705-4713.
45. Morishita K, Parganas E, Douglass EC, Ihle JN. Unique expression of the human Evi-1 gene in an endometrial carcinoma cell line: sequence of cDNAs and structure of alternatively spliced transcripts. Oncogene 1990, 5(7):963-971.
46. Fears S, Mathieu C, Zeleznik-Le N, Huang S, Rowley JD, Nucifora G. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc Natl Acad Sci USA 1996, 93(4):1642-1647. 10.1073/pnas.93.4.1642, 39995, 8643684.
47. Kaye SB. Reversal of drug resistance in ovarian cancer: where do we go from here?. J Clin Oncol 2008, 26(16):2616-2618. 10.1200/JCO.2008.16.2123, 18509172.
48. Wang YC, Juric D, Francisco B, Yu RX, Duran GE, Chen GK, Chen X, Sikic BI. Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines. Genes Chromosomes Cancer 2006, 45(4):365-374. 10.1002/gcc.20300, 16382445.
49. Yabuki N, Sakata K, Yamasaki T, Terashima H, Mio T, Miyazaki Y, Fujii T, Kitada K. Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. Cancer Genet Cytogenet 2007, 173(1):1-9. 10.1016/j.cancergencyto.2006.07.020, 17284363.
50. Kitada K, Yamasaki T. The complicated copy number alterations in chromosome 7 of a lung cancer cell line is explained by a model based on repeated breakage-fusion-bridge cycles. Cancer Genet Cytogenet 2008, 185(1):11-19. 10.1016/j.cancergencyto.2008.04.005, 18656688.
51. Codegoni AM, Broggini M, Pitelli MR, Pantarotto M, Torri V, Mangioni C, D'Incalci M. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol Oncol 1997, 65(1):130-137. 10.1006/gyno.1996.4609, 9103402.